… of the malaria vaccine SPf66 in Africa, MOIs in SPf66- and placebo-vaccinated children were
… MOIs were significantly reduced in asymptomatic vaccine recipients compared with those in …

… As part of the programme to evaluate SPf66 as a potential tool for malaria control in Africa, …
However, SPf66 did not reduce the risk of clinical malaria among Tanzanian children living …

… index of malaria were found between the two groups of children. … on SPf66 efficacy from
South America and from Tanzania. In … of malaria during the rainy season after immunisation in …

… merozoite derived sequences contained in the malaria vaccine SPf66 (83.1, 55.1 and 35.1)
… the SPf66 vaccine induce a strong IgG antibody response against both the SPf66 construct, …

… We have completed a trial of the peptide vaccine SPf66 in Tanzanian infants, given … of
the effects of the SPf66 malaria vaccine in African children exposed to intense transmission of …

… of clinical malaria among Tanzanian children who had received the SPf66 malaria vaccine
developed by Pattaroyo. These results were obtained in an area where malaria transmission …

… -up, while further supplies of SPf66 were prepared and transported to Tanzania. In the first
week of February 1995, SPf66 was offered to children who had previously received placebo, …

… America and evidence of borderline efficacy from Tanzania. We conclude that SPf66 does
not protect against clinical falciparum malaria and that further efficacy trials are not warranted. …

… first field trial of the SPf66 malaria vaccine in children under 12 months of … malaria vaccine
SPf66 in Tanzanian children’ and Gambian infants (D’Alessandro and colleagues), vaccine …

… In Tanzania, SPf66 reduced the risk of clinical malaria by 31% in children aged 1–5 years. …
development and testing towards the implementation of a new vaccine in malaria control …